Published in Eur J Pharmacol on July 07, 1992
Nomenclature and classification of purinoceptors. Pharmacol Rev (1994) 5.32
P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels. EMBO J (1998) 3.23
Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. Proc Natl Acad Sci U S A (2001) 2.36
The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol (2011) 2.33
Pharmacology of P2X channels. Pflugers Arch (2006) 2.14
Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors. Br J Pharmacol (1994) 1.77
PPADS selectively antagonizes P2X-purinoceptor-mediated responses in the rabbit urinary bladder. Br J Pharmacol (1993) 1.69
PPADS and suramin as antagonists at cloned P2Y- and P2U-purinoceptors. Br J Pharmacol (1996) 1.32
Vasoconstrictor and vasodilator responses to various agonists in the rat perfused mesenteric arterial bed: selective inhibition by PPADS of contractions mediated via P2x-purinoceptors. Br J Pharmacol (1994) 1.27
Selective antagonism by PPADS at P2X-purinoceptors in rabbit isolated blood vessels. Br J Pharmacol (1994) 1.27
Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms. Br J Pharmacol (2003) 1.25
P2X purinoceptors in cultured myenteric neurons of guinea-pig small intestine. J Physiol (1996) 1.25
PPADS: an antagonist at endothelial P2Y-purinoceptors but not P2U-purinoceptors. Br J Pharmacol (1995) 1.23
Investigation of the actions of PPADS, a novel P2x-purinoceptor antagonist, in the guinea-pig isolated vas deferens. Br J Pharmacol (1994) 1.18
Pivotal role of phosphate chain length in vasoconstrictor versus vasodilator actions of adenine dinucleotides in rat mesenteric arteries. J Physiol (1995) 1.16
Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 264.7 macrophages. Br J Pharmacol (1996) 1.16
Mechanism of action of ATP on canine pulmonary vagal C fibre nerve terminals. J Physiol (1996) 1.14
Discrimination by PPADS between endothelial P2Y- and P2U-purinoceptors in the rat isolated mesenteric arterial bed. Br J Pharmacol (1996) 1.09
Cysteine scanning mutagenesis (residues Glu52-Gly96) of the human P2X1 receptor for ATP: mapping agonist binding and channel gating. J Biol Chem (2011) 1.05
Purinergic signalling in the urinary tract in health and disease. Purinergic Signal (2013) 1.01
The use of antagonists to characterize the receptors mediating depolarization of the rat isolated vagus nerve by alpha, beta-methylene adenosine 5'-triphosphate. Br J Pharmacol (1994) 0.98
Inhibitory action of PPADS on relaxant responses to adenine nucleotides or electrical field stimulation in guinea-pig taenia coli and rat duodenum. Br J Pharmacol (1995) 0.96
Ionotropic P2X purinoreceptors mediate synaptic transmission in rat pyramidal neurones of layer II/III of somato-sensory cortex. J Physiol (2002) 0.96
Synthesis and Structure-Activity Relationships of Pyridoxal-6-arylazo-5'-phosphate and Phosphonate Derivatives as P2 Receptor Antagonists. Drug Dev Res (1998) 0.96
Comparative studies on the affinities of ATP derivatives for P2x-purinoceptors in rat urinary bladder. Br J Pharmacol (1994) 0.95
Differentiation by pyridoxal 5-phosphate, PPADS and IsoPPADS between responses mediated by UTP and those evoked by alpha, beta-methylene-ATP on rat sympathetic ganglia. Br J Pharmacol (1995) 0.95
Evidence for the Recognition of Non-Nucleotide Antagonists Within the Transmembrane Domains of the Human P2Y(1) Receptor. Drug Dev Res (2002) 0.95
Evidence for a P2-purinoceptor mediating vasoconstriction by UTP, ATP and related nucleotides in the isolated pulmonary vascular bed of the rat. Br J Pharmacol (1996) 0.94
Modulation by endogenous ATP of the light-evoked release of ACh from retinal cholinergic neurones. Br J Pharmacol (1994) 0.94
Investigation of the effects of P2 purinoceptor ligands on the micturition reflex in female urethane-anaesthetized rats. Br J Pharmacol (2004) 0.93
Pannexin 1 regulates postnatal neural stem and progenitor cell proliferation. Neural Dev (2012) 0.93
P2x-purinoceptors of myenteric neurones from the guinea-pig ileum and their unusual pharmacological properties. Br J Pharmacol (1996) 0.91
Novel data point to a broader mechanism of action of oxidized ATP: the P2X7 receptor is not the only target. Br J Pharmacol (2003) 0.90
Neural progenitor cells regulate capillary blood flow in the postnatal subventricular zone. J Neurosci (2012) 0.89
Topical application of PPADS inhibits complement activation and choroidal neovascularization in a model of age-related macular degeneration. PLoS One (2013) 0.86
Relative contribution of P2U- and P2Y-purinoceptors to endothelium-dependent vasodilatation in the golden hamster isolated mesenteric arterial bed. Br J Pharmacol (1996) 0.86
The possible role of ATP and PACAP as mediators of apaminsensitive NANC inhibitory junction potentials in circular muscle of guinea-pig colon. Br J Pharmacol (1996) 0.86
P2 purinoceptor-mediated depolarization of rat supraoptic neurosecretory cells in vitro. J Physiol (1995) 0.86
Characterization of the ATPase released during sympathetic nerve stimulation of the guinea-pig isolated vas deferens. Br J Pharmacol (2000) 0.85
Molecular recognition in P2 receptors: ligand development aided by molecular modeling and mutagenesis. Prog Brain Res (1999) 0.84
Shock wave treatment enhances cell proliferation and improves wound healing by ATP release-coupled extracellular signal-regulated kinase (ERK) activation. J Biol Chem (2014) 0.84
The role of purinergic receptors in cancer-induced bone pain. J Osteoporos (2012) 0.83
Structure-activity relationships of diadenosine polyphosphates (Ap(n)As), adenosine polyphospho guanosines (Ap(n)Gs) and guanosine polyphospho guanosines (Gp(n)Gs) at P2 receptors in the rat mesenteric arterial bed. Br J Pharmacol (2001) 0.82
Both RyRs and TPCs are required for NAADP-induced intracellular Ca²⁺ release. Cell Calcium (2015) 0.82
The effects of purine compounds on the isolated aorta of the frog Rana temporaria. Br J Pharmacol (1996) 0.82
Involvement of P2X receptors in the NAD(+)-induced rise in [Ca (2+)] (i) in human monocytes. Purinergic Signal (2009) 0.82
P2X2 and P2Y1 immunofluorescence in rat neostriatal medium-spiny projection neurones and cholinergic interneurones is not linked to respective purinergic receptor function. Br J Pharmacol (2004) 0.82
The plasminogen activator system modulates sympathetic nerve function. J Exp Med (2006) 0.82
Responses of the aorta of the garter snake (Thamnophis sirtalis parietalis) to purines. Br J Pharmacol (1995) 0.80
Purinergic modulation of cardiovascular function in the rat locus coeruleus. Br J Pharmacol (2005) 0.80
Key sites for P2X receptor function and multimerization: overview of mutagenesis studies on a structural basis. Curr Med Chem (2015) 0.80
The effect of PPADS as an antagonist of inositol (1,4,5)trisphosphate induced intracellular calcium mobilization. Br J Pharmacol (1996) 0.80
Characterization of the P2Y-purinoceptor involved in the ATP-induced rise in cytosolic Ca2+ concentration in rat ileal myocytes. Br J Pharmacol (1996) 0.80
Potentiation of sympathetic neuromuscular transmission mediated by muscarinic receptors in guinea pig isolated vas deferens. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.79
High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors. Assay Drug Dev Technol (2015) 0.79
Actions of a Series of PPADS Analogs at P2X1 and P2X3 Receptors. Drug Dev Res (2001) 0.79
Effects of PPADS and suramin on contractions and cytoplasmic Ca2+ changes evoked by AP4A, ATP and alpha, beta-methylene ATP in guinea-pig urinary bladder. Br J Pharmacol (1996) 0.78
P2-purinoceptors mediating spasm of the isolated uterus of the non-pregnant guinea-pig. Br J Pharmacol (1996) 0.78
Biphasic neurogenic vasodilatation in the bovine intraocular long posterior ciliary artery: involvement of nitric oxide and an additional unidentified neurotransmitter. Br J Pharmacol (2005) 0.78
Evidence for two distinct P2-purinoceptors subserving contraction of the rat anococcygeus smooth muscle. Br J Pharmacol (1996) 0.78
Development of a comprehensive set of P2 receptor pharmacological research compounds. Purinergic Signal (2011) 0.78
Vasoconstrictor responses to the P2x-purinoceptor agonist beta, gamma-methylene-L-ATP in human cutaneous and renal blood vessels. Br J Pharmacol (1995) 0.78
Permeation of fluorophore-conjugated phalloidin into live hair cells of the inner ear is modulated by P2Y receptors. J Assoc Res Otolaryngol (2013) 0.76
P(2) purinoceptors account for the non-nitrergic NANC relaxation in the rat ileum. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.76
Blockade of P2X-purinoceptors by trypan blue in rat vas deferens. Br J Pharmacol (1994) 0.76
Inhibition of Ecto-Apyrase and Ecto-ATPase by Pyridoxal Phosphate-Related Compounds. Drug Dev Res (2000) 0.75
A critical look at the function of the P2Y11 receptor. Purinergic Signal (2016) 0.75
Poster communications. Br J Pharmacol (1993) 0.75
P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels. EMBO J (1998) 3.23
Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther (1991) 2.55
PPADS selectively antagonizes P2X-purinoceptor-mediated responses in the rabbit urinary bladder. Br J Pharmacol (1993) 1.69
Judging social issues: difficulties, inconsistencies, and consistencies. Monogr Soc Res Child Dev (1991) 1.56
[Structure-activity relationship of N-methyl-3-pyrroline and N-methyl-pyrrolidine-3-carboxylic acid]. Arzneimittelforschung (1971) 1.40
Study of the contractile effect of 5-hydroxytryptamine (5-HT) in the isolated longitudinal muscle strip from guinea-pig ileum. Evidence for two distinct release mechanisms. Naunyn Schmiedebergs Arch Pharmacol (1985) 1.36
[Structure-activity relationships of unsaturated esters of arecaidine and dihydroarecaidine]. Arzneimittelforschung (1973) 1.35
Selective antagonism by PPADS at P2X-purinoceptors in rabbit isolated blood vessels. Br J Pharmacol (1994) 1.27
Vasoconstrictor and vasodilator responses to various agonists in the rat perfused mesenteric arterial bed: selective inhibition by PPADS of contractions mediated via P2x-purinoceptors. Br J Pharmacol (1994) 1.27
Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int (1997) 1.27
Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine. Klin Wochenschr (1982) 1.26
Interaction of cimetidine with metoprolol, propranolol, or atenolol. Lancet (1981) 1.22
RNA-protein neighbourhoods of the ribosome obtained by crosslinking. Eur J Biochem (1978) 1.21
Investigation of the actions of PPADS, a novel P2x-purinoceptor antagonist, in the guinea-pig isolated vas deferens. Br J Pharmacol (1994) 1.18
Fluorimetric determination of atenolol in plasma and urine by direct evaluation of thin-layer chromatograms. J Chromatogr (1979) 1.18
Fluorimetric determination of oxprenolol in plasma by direct evaluation of thin-layer chromatograms. J Chromatogr (1979) 1.17
p-fluoro-hexahydro-sila-difenidol: the first M2 beta-selective muscarinic antagonist. Eur J Pharmacol (1988) 1.16
Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int (1999) 1.14
Functional assessments for decision-making regarding return to sports following ACL reconstruction. Part II: clinical application of a new test battery. Knee Surg Sports Traumatol Arthrosc (2015) 1.14
Antimuscarinic action of methoctramine, a new cardioselective M-2 muscarinic receptor antagonist, alone and in combination with atropine and gallamine. Eur J Pharmacol (1987) 1.13
Pharmacological characterization of the vascular muscarinic receptors mediating relaxation and contraction in rabbit aorta. J Pharmacol Exp Ther (1991) 1.12
Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors. J Biol Chem (1994) 1.07
Characterisation of a new, fully active fluorescent derivative of E. coli tRNA Phe. Nucleic Acids Res (1980) 1.03
Affinity profiles of hexahydro-sila-difenidol analogues at muscarinic receptor subtypes. Eur J Pharmacol (1989) 1.01
Muscarinic receptors mediating acid secretion in isolated rat gastric parietal cells are of M3 type. Gastroenterology (1990) 1.00
Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers. Antimicrob Agents Chemother (1987) 0.99
NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors. Naunyn Schmiedebergs Arch Pharmacol (2001) 0.97
Inhibitory action of PPADS on relaxant responses to adenine nucleotides or electrical field stimulation in guinea-pig taenia coli and rat duodenum. Br J Pharmacol (1995) 0.96
Presynaptic muscarinic receptors mediating inhibition of neurogenic contractions in rabbit vas deferens are of the ganglionic M1-type. Eur J Pharmacol (1988) 0.96
[On the microbiological conversion of N-containing substrates. 4. On the microbiological conversion of 5-hydroxyindole through Clavic eps purpurea, Cordyceps militaris and Aspergillus oryzae]. Arch Pharm Ber Dtsch Pharm Ges (1968) 0.95
o-Methoxy-sila-hexocyclium: a new quaternary M1-selective muscarinic antagonist. Eur J Pharmacol (1988) 0.95
Influence of ranitidine on plasma metoprolol and atenolol concentrations. Br Med J (Clin Res Ed) (1983) 0.95
Cefodizime penetration into skin suction blister fluid following a single intravenous dose. Eur J Clin Pharmacol (1986) 0.95
The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects. Eur J Clin Pharmacol (2006) 0.95
Atenolol interaction with aspirin, allopurinol, and ampicillin. Clin Pharmacol Ther (1983) 0.94
Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay. Clin Pharmacol Ther (1999) 0.94
Different binding affinities of NMDA receptor channel blockers in various brain regions--indication of NMDA receptor heterogeneity. Neuropharmacology (1995) 0.94
NF279: a novel potent and selective antagonist of P2X receptor-mediated responses. Eur J Pharmacol (1998) 0.94
Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol (1995) 0.94
Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol (1997) 0.93
Characterization of the prejunctional muscarinic receptors mediating inhibition of evoked release of endogenous noradrenaline in rabbit isolated vas deferens. Naunyn Schmiedebergs Arch Pharmacol (1994) 0.93
Vasoconstrictor responses via P2X-receptors are selectively antagonized by NF023 in rabbit isolated aorta and saphenous artery. Br J Pharmacol (1997) 0.93
Increase in magnesium plasma level after orally administered trimagnesium dicitrate. Eur J Clin Pharmacol (1996) 0.92
Methoctramine selectively blocks cardiac muscarinic M2 receptors in vivo. Naunyn Schmiedebergs Arch Pharmacol (1988) 0.92
Human HT-29 colon carcinoma cells contain muscarinic M3 receptors coupled to phosphoinositide metabolism. Eur J Pharmacol (1989) 0.92
Characterization of muscarinic receptors mediating vasodilation in rat perfused kidney. Eur J Pharmacol (1993) 0.92
Limitation on the use of amiloride in early renal failure. Eur J Clin Pharmacol (1985) 0.92
Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol (2000) 0.91
[Fluorimetric determination of amiloride in human plasma using thin-layer chromatography]. J Chromatogr (1982) 0.91
In vitro antispasmodic compounds of the dry extract obtained from Hedera helix. Planta Med (1997) 0.91
Muscarinic acetylcholine receptors: structural basis of ligand binding and G protein coupling. Life Sci (1995) 0.91
[Fluorometric determination of propranolol and its metabolite n-desisopropylpropranolol in plasma and urine by direct meausrement of thin-layer chromatographic plates (author's transl]. J Chromatogr (1977) 0.91
Bioavailability study of two different verapamil formulations. Arch Pharm (Weinheim) (1992) 0.90
Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. Eur J Clin Pharmacol (1999) 0.89
The novel pyridoxal-5'-phosphate derivative PPNDS potently antagonizes activation of P2X(1) receptors. Eur J Pharmacol (2000) 0.89
A comparison of the antimuscarinic effects of pirenzepine and N-methylatropine on ganglionic and vascular muscarinic receptors in the rat. Life Sci (1984) 0.89
Blockade of epithelial Na+ channels by triamterenes - underlying mechanisms and molecular basis. Pflugers Arch (1996) 0.89
Muscarinic receptor subtypes in rat pancreatic islets: binding and functional studies. Eur J Pharmacol (1990) 0.88
Human gastric mucosa expresses glandular M3 subtype of muscarinic receptors. Dig Dis Sci (1990) 0.88
Delayed elimination of triamterene and its active metabolite in chronic renal failure. Eur J Clin Pharmacol (1983) 0.88
Predictability of the covalent binding of acidic drugs in man. Life Sci (1993) 0.87
Functional role of a cytoplasmic aromatic amino acid in muscarinic receptor-mediated activation of phospholipase C. J Biol Chem (1994) 0.87
Intraoperative tramadol reduces shivering but not pain after remifentanil-isoflurane general anaesthesia. A placebo-controlled, double-blind trial. Eur J Anaesthesiol (2008) 0.87
Influence of ranitidine on plasma metoprolol concentrations. Br Med J (Clin Res Ed) (1983) 0.87
Pharmacokinetics of atenolol in relation to renal function. Eur J Clin Pharmacol (1981) 0.87
Binding and functional properties of antimuscarinics of the hexocyclium/sila-hexocyclium and hexahydro-diphenidol/hexahydro-sila-diphenidol type to muscarinic receptor subtypes. Br J Pharmacol (1989) 0.87
[Determination and comparison of the plasma and urine concentrations in men given tranylcypromine stereoisomers]. Arzneimittelforschung (1979) 0.87
Human plasma and skin blister fluid levels of griseofulvin following a single oral dose. Eur J Clin Pharmacol (1985) 0.87
HPLC assays to simultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP 3174 in biological material of humans and rats. J Pharm Biomed Anal (1998) 0.86
New functionally selective muscarinic agonists. Life Sci (1993) 0.86
Blue native PAGE as a useful method for the analysis of the assembly of distinct combinations of nicotinic acetylcholine receptor subunits. J Recept Signal Transduct Res (1999) 0.85
Different muscarine receptors mediate the prejunctional inhibition of [3H]-noradrenaline release in rat or guinea-pig iris and the contraction of the rabbit iris sphincter muscle. Naunyn Schmiedebergs Arch Pharmacol (1989) 0.85
Ketoconazole concentrations in human skin blister fluid and plasma. Int J Clin Pharmacol Ther Toxicol (1984) 0.85
Pharmacokinetics of amiloride in renal and hepatic disease. Eur J Clin Pharmacol (1987) 0.85
Does cantharides blister fluid provide access to the peripheral compartment? Eur J Clin Pharmacol (1982) 0.85
Cross-linking techniques. Methods Enzymol (1989) 0.84
Novel pharmacological profile of muscarinic receptors mediating contraction of the guinea-pig uterus. Naunyn Schmiedebergs Arch Pharmacol (1990) 0.84
Fluorimetric determination of the quaternary compound trospium and its metabolite in biological material after derivatization with benoxaprofen chloride. J Chromatogr (1985) 0.84
Selective antagonists provide evidence that M1 muscarinic receptors may mediate carbachol-induced drinking in the rat. Eur J Pharmacol (1990) 0.84
Stereoselectivity of the enantiomers of trihexyphenidyl and its methiodide at muscarinic receptor subtypes. Eur J Pharmacol (1988) 0.84
Interaction between the beta-adrenoceptor blockers metoprolol and atenolol with amitriptyline and their effects on oxidative liver metabolism. Br J Clin Pharmacol (1984) 0.83
Pharmacodynamics and pharmacokinetics of furosemide combinations with potassium-retaining and thiazide-like diuretics: clearance and micropuncture studies. Naunyn Schmiedebergs Arch Pharmacol (1986) 0.83
Pharmacokinetics of hydrochlorothiazide in relation to renal function. Eur J Clin Pharmacol (1983) 0.83
Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm Res (1996) 0.83
Clinical experience with atenolol in patients with chronic liver disease. J Clin Pharmacol (1983) 0.82
Noncollinear magnetic order in quasicrystals. Phys Rev Lett (2004) 0.82